About Us
TicTwo was founded in 2024 and is funded thru IND submission.
The Company is focused on developing brain penetrant TYK2 inhibitors to block neuroinflammation which is recognized as a driver of neurodegenerative diseases including Alzheimer’s Disease and Frontotemporal Dementia (FTD).
Our Science
Learn more about the science behind our innovative approach to neurodegenerative treatment.